News & Updates
Filter by Specialty:
What is the most preferred first-line agent for paediatric alopecia areata?
In the treatment of paediatric alopecia areata (AA), an autoimmune, nonscarring hair loss disorder with a variable disease course and significant psychosocial impact, the most preferred first-line agent is topical corticosteroids, followed by contact immunotherapy, according to a study.
What is the most preferred first-line agent for paediatric alopecia areata?
25 May 2022
Upadacitinib provides robust, long-term control of moderate-to-severe AD
Follow-up data from two replicate ongoing phase III trials – Measure Up 1 and Measure Up 2 – demonstrated favourable longer-term benefit-risk profile of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis (AD).
Upadacitinib provides robust, long-term control of moderate-to-severe AD
23 May 2022
Lirentelimab shows promise in treatment-resistant chronic urticaria
In patients who suffer from antihistamine-resistant chronic urticaria (CU), lirentelimab seems to be effective at controlling the disease and reducing disease activity, reports a recent study.
Lirentelimab shows promise in treatment-resistant chronic urticaria
14 May 2022
Depression, anxiety aggravated in vitiligo patients
Vitiligo patients suffer from greater levels of depression and anxiety, both of which appear to be associated with serum levels of corticotropin releasing hormone, reveals a recent study.